NasdaqCM:VKTXBiotechs
Is It Too Late To Revisit Viking Therapeutics (VKTX) After Its Multi Year Surge?
Wondering if Viking Therapeutics at around US$33.20 is still offering value after a strong multi year run, or if the easy gains are already behind it.
The stock has seen a 1% decline over the past week and a 3.7% decline over the last month, even with a 26% return over the past year and a very large gain over five years.
Recent attention on Viking Therapeutics has been driven by its role in the pharmaceuticals and biotech space. In this area, clinical progress, partnerships, or regulatory...